Cellectar Biosciences, Inc.CLRBNASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | 25.18% |
| Q3 2025 | 5.59% |
| Q2 2025 | -30.27% |
| Q1 2025 | -44.81% |
| Q4 2024 | 13.03% |
| Q3 2024 | -25.21% |
| Q2 2024 | 3.63% |
| Q1 2024 | -10.69% |
| Q4 2023 | 12.82% |
| Q3 2023 | 14.66% |
| Q2 2023 | -3.53% |
| Q1 2023 | 16.60% |
| Q4 2022 | 1.37% |
| Q3 2022 | 19.60% |
| Q2 2022 | 15.73% |
| Q1 2022 | -11.42% |
| Q4 2021 | 11.45% |
| Q3 2021 | -14.91% |
| Q2 2021 | -0.12% |
| Q1 2021 | 95.08% |
| Q4 2020 | -11.51% |
| Q3 2020 | 8.86% |
| Q2 2020 | -5.77% |
| Q1 2020 | 20.33% |
| Q4 2019 | -19.59% |
| Q3 2019 | 49.42% |
| Q2 2019 | -21.61% |
| Q1 2019 | 122.67% |
| Q4 2018 | -48.05% |
| Q3 2018 | 15.81% |
| Q2 2018 | -18.88% |
| Q1 2018 | -31.48% |
| Q4 2017 | 32.86% |
| Q3 2017 | 7.22% |
| Q2 2017 | 17.18% |
| Q1 2017 | 28.94% |
| Q4 2016 | 10.31% |
| Q3 2016 | 35.27% |
| Q2 2016 | -7.15% |
| Q1 2016 | 7.81% |